Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Loading...
Date
2010
Journal Title
Journal ISSN
Volume Title
Publisher
Biomed Central
Abstract
Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to
men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap for
sexually active women who are unable to successfully negotiate mutual monogamy or condom use.
Purpose: This paper describes the baseline sample characteristics in the CAPRISA 004 trial which assessed the
safety and effectiveness of the vaginal microbicide, 1% tenofovir gel for HIV prevention in South Africa.
Methods: This analysis assessed the baseline demographic, clinical and sexual behavior data of women screened
and enrolled into the trial. The characteristics were summarized using descriptive summary measures; expressed as
means and percent for categorical variables. Results: HIV prevalence at screening was 25.8% [95% Confidence Interval (CI):23.9-27.7). Of the 889 eligibly enrolled women who contributed follow-up data, rural participants recruited from a family planning (FP) clinic were
younger, more likely to be living apart from their regular partner, reported lower coital frequency, had lower
condom use (p < 0.001). In contrast, urban participants recruited from a sexually transmitted disease (STD) clinic
reported higher numbers of lifetime sexual partners, new partners in the last 30 days and receiving money in
exchange for sex (p < 0.001). Conclusion: The populations selected provide suitable diverse target groups for HIV prevention intervention studies.
Description
Keywords
Biomedical research., Clinical trials., HIV infections--Prevention--South Africa.
Citation
Karim Q.A., Kharsany A.B., Frohlich J.A., et al. 2011. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials 12 pp.67-75.